Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer

NCT00150995 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00150995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00150995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2001
Completion date
April 30, 2006
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer